Geranylgeraniol

Geranylgeraniol is an orally acitve vitamin K2 sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model[1][2][3][4].

Product Specifications

CAS Number

[24034-73-9]

UNSPSC

12352211

Hazard Statement

H315, H319, H335

Target

NF-κB

Type

Natural Products

Related Pathways

NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/geranylgeraniol.html

Purity

99.28

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C/C(C)=C\CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CO

Molecular Formula

C20H34O

Molecular Weight

290.48

Precautions

H315, H319, H335

References & Citations

[1]Saputra WD, et al. Geranylgeraniol Inhibits Lipopolysaccharide-Induced Inflammation in Mouse-Derived MG6 Microglial Cells via NF-κB Signaling Modulation. Int J Mol Sci. 2021 Sep 29;22 (19) :10543. |[2]Marcuzzi A, et al. Geranylgeraniol and Neurological Impairment: Involvement of Apoptosis and Mitochondrial Morphology. Int J Mol Sci. 2016 Mar 11;17 (3) :365. |[3]Preece K, et al. A toxicological evaluation of geranylgeraniol. Regul Toxicol Pharmacol. 2021 Aug;124:104975. |[4]Giriwono PE, et al. Dietary supplementation with geranylgeraniol suppresses lipopolysaccharide-induced inflammation via inhibition of nuclear factor-κB activation in rats. Eur J Nutr. 2013 Apr;52 (3) :1191-9.